A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies

Oncogene

Volumn 34, Issue 26, 2015, Pages 3357-3368

  Althoff, K ^a,b   Beckers, A ^c   Bell, E ^b   Nortmeyer, M ^b   Thor, T ^a,b   Sprussel A ^a,b   Lindner, S ^a,b   De Preter, K ^c   Florin, A ^d   Heukamp, L C ^d,e   Klein Hitpass, L ^f   Astrahantseff, K ^g   Kumps, C ^c   Speleman, F ^c   Eggert, A ^g   Westermann, F ^b   Schramm, A ^a   Schulte, J H ^a,b,c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e NEO New Oncology GmbH   (Germany)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; ALISERTIB; CRE RECOMBINASE; DOPAMINE BETA MONOOXYGENASE; NERVE CELL ADHESION MOLECULE; TYROSINE 3 MONOOXYGENASE; INTEGRASE; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; HISTOPATHOLOGY; MOUSE; NEURAL CREST; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; TUMOR LOCALIZATION; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MICROARRAY ANALYSIS; NUDE MOUSE; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES; PROMOTER REGION; TRANSGENE; TRANSGENIC MOUSE; TUMOR CELL CULTURE;

MUS; MUS MUSCULUS;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTEGRASES; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; MICROARRAY ANALYSIS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROMOTER REGIONS, GENETIC; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 84933040610     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.269     Document Type: Article

References (44)

1. Ora I, Eggert A. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research. Semin Cancer Biol 2011; 21: 217-228.
2. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010; 24: 65-86.
3. Jiang M, Stanke J, Lahti JM. The connections between neural crest development and neuroblastoma. Curr Top Dev Biol 2011; 94: 77-127.
4. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-2211.
5. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216.
6. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16: 2985-2995.
7. Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci USA 2004; 101: 12664-12669.
8. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005; 23: 2280-2299.
9. Stallings RL, Howard J, Dunlop A, Mullarkey M, McDermott M, Breatnach F et al. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma? Cancer Genet Cytogenet 2003; 140: 133-137.
10. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 2010; 28: 3122-3130.
11. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
12. Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 2007; 67: 32-40.
13. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
14. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 2008; 9: R150.
15. Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Science translational medicine 2012; 4: 141ra91.
16. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 2013; 3: 308-323.
17. Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 2013; 24: 75-89.
18. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatric Blood Cancer 2011; 56: 578-583.
19. Stanke M, Duong CV, Pape M, Geissen M, Burbach G, Deller T et al. Targetdependent specification of the neurotransmitter phenotype: cholinergic differentiation of sympathetic neurons is mediated in vivo by gp 130 signaling. Development 2006; 133: 141-150.
20. Weiss WA, Godfrey T, Francisco C, Bishop JM. Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res 2000; 60: 2483-2487.
21. Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ et al. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 2003; 63: 5266-5273.
22. Molenaar JJ, Domingo-Fernandez R, Ebus ME, Lindner S, Koster J, Drabek K et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genetics 2012; 44: 1199-1206.
23. Casola S. Mouse models for miRNA expression: the ROSA26 locus. Methods Mol Biol 2010; 667: 145-163.
24. Tchorz JS, Suply T, Ksiazek I, Giachino C, Cloetta D, Danzer CP et al. A modified RMCE-compatible Rosa26 locus for the expression of transgenes from exogenous promoters. PLoS One 2012; 7: e30011.
25. Rasmuson A, Segerstrom L, Nethander M, Finnman J, Elfman LH, Javanmardi N et al. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS ONE 2012; 7: e51297.
26. Gargano B, Amente S, Majello B, Lania L. P-TEFb is a crucial co-factor for Myc transactivation. Cell Cycle 2007; 6: 2031-2037.
27. Eberhardy SR, Farnham PJ. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J Biol Chem 2002; 277: 40156-40162.
28. Yang Z, He N, Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol Cell Biol 2008; 28: 967-976.
29. Schramm A, Vandesompele J, Schulte JH, Dreesmann S, Kaderali L, Brors B et al. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. Clin Cancer Res 2007; 13: 1459-1465.
30. Schulte JH, Bachmann HS, Brockmeyer B, Depreter K, Oberthur A, Ackermann S et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 2011; 17: 5082-5092.
31. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer research 2009; 69: 2065-2071.
32. Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S et al. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 2012; 32: 1059-1065.
33. Menten B, Pattyn F, De Preter K, Robbrecht P, Michels E, Buysse K et al. arrayCGHbase: an analysis platform for comparative genomic hybridization microarrays. BMC Bioinformatics 2005; 6: 124.
34. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004; 5: 557-572.
35. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
36. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome biology 2009; 10(6): R64.
37. De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I et al. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res 2011; 17: 7684-7692.
38. Mootha VK, Bunkenborg J, Olsen JV, Hjerrild M, Wisniewski JR, Stahl E et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 2003; 115: 629-640.
39. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011; 27: 1739-1740.
40. Fredlund E, Ringner M, Maris JM, Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 2008; 105: 14094-14099.
41. Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010; 29: 1394-1404.
42. Cimmino F, Schulte JH, Zollo M, Koster J, Versteeg R, Iolascon A et al. Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. Oncogene 2009; 28: 2015-2023.
43. Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinskchmidt C, Christiansen H et al. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?. Medical and pediatric oncology 2001; 36: 5-10.
44. Hong F, Wittner B, Breitling R, Smith C, Battke F et al. RankProd: Rank Product method for identifying differentially expressed genes with application in metaanalysis. R package version 2011; 2.34.0.